ArticlePLOS global public health2026
Uganda's cholera elimination journey in a cholera endemic region of Africa.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uganda has been endemic for cholera since 1971. To reduce the threat of cholera, Uganda reviewed its approach to cholera, emphasizing surveillance, continued using single dose doxycycline for cholera patients and their households, and conducted 16 oral cholera vaccine campaigns in high-risk districts between 2018 and 2021.To understand recent changes in cholera patternsand the impact of the OCV campaigns, we classified districts as endemic, eliminated, or relapsed using the method as defined by the "cholera elimination scorecard" for the years 2018-2024 using cholera surveillance data from the Ministry of Health. We also reviewed Uganda's policy regarding cholera surveillance and antibiotic use for cholera patients and their immediate households. To understand risks from cross-border cholera transmission, we reviewed cholera reports from the other countries in the East African Community. During the 16 campaigns with OCV (each campaign with two rounds), 2,263,790 people living in high risk subcounties of the hotspot districts were targeted for vaccination. Overall administrative vaccine coverage was 94% for the first round and 84% for the second round. Based on national surveillance data, the number of endemic districts fell from 36 prior to the campaigns to six after the campaigns. To identify new outbreaks and reduce the threat from cholera, Uganda implemented enhanced cholera surveillance, especially in the border areas, and administered single dose doxycycline to all cholera patients and their households with the intention to treat them and prevent spread of the outbreak. Since 2021, all cholera outbreaks in Uganda have been epidemiologically linked with cross-border spread from neighboring countries.Uganda has eliminated endogenous cholera (that is, cholera originating from within the country), but it remains vulnerable to cholera from neighboring countries in the region. Uganda's experience to control cholera may be useful for other countries in Africa which are attempting to eliminate this disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.